A New Topical Testosterone Enhancer by Eli Lilly

Eli Lilly and Company, the manufacturer of the popular erectile dysfunction drug Cialis (tadalafil), has signed an exclusive worldwide license to market and sell a new testosterone enhancement drug called Axiron. The drug, which is still in experimental and review stages, was developed by Acrux Ltd, an Australian biotech company focused on developing transdermal drug delivery systems (the administration of medicine through the skin). Axiron will be available as a lotion or a patch.

Men who suffer from low libido as a result of low testosterone levels will benefit from Axiron, which can boost their testosterone to a normal level and help them enjoy better sex drive and improved erectile function.

The drug was submitted by Lilly for FDA approval and global marketing authorization. If approved, Axiron will enter the highly competitive, $1 billion market of testosterone therapies.

About 40% of men aged 45 and older suffer from some degree of testosterone deficiency, which results in weakened sexual ability. This new medicine will add a new option for low testosterone patients who are usually prescribed rub-on gels, patches, or intramuscular injections.